article thumbnail

Research finds many oncology drugs have ‘little or no added benefit’

Hospital Pharmacy Europe

Many oncology drugs approved by the European Medicines Agency (EMA) between 2005 and 2020 provide ‘little or no added benefit’ for patients, according to new research. Many drugs with higher benefit ratings were associated with more significant revenues for the associated pharmaceutical companies, they added.

article thumbnail

The Ripple Effect: How Pharmaceutical Advertisements Impact the Industry and Beyond

Pharma Marketing Network

Pharmaceutical advertisements play a significant role in shaping the industry as a whole, influencing both consumer behavior and healthcare provider practices. For example, advertisements can increase demand for certain medications, leading to increased sales and profits for pharmaceutical companies. References: 1. Goozner, M.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

A history of AstraZeneca

pharmaphorum

But although it was dubbed a “dangerous game”, some companies came out on top… On 6th April 1999, two companies with similar science-based cultures and a shared vision of the pharmaceutical industry came together to form what’s now considered as one of the top ten pharma companies in the world: AstraZeneca.

Vaccines 116
article thumbnail

Pharma within planetary boundaries

European Pharmaceutical Review

4 Together with a legal expert from the Bucerius Law School Hamburg, we looked at the legal and political frameworks that could enable the German pharmaceutical sector to become more sustainable.

article thumbnail

IoT innovation: Leading companies in nanoparticles for drug delivery

Pharmaceutical Technology

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. Bristol-Myers Squibb is the leading patent filer in nanoparticles for drug delivery.

article thumbnail

Patents: a necessary evil?

European Pharmaceutical Review

Patents are often described as the ‘lifeblood’ of pharmaceutical companies. 1 However, patent protection for pharmaceutical products is an economic trade-off between providing monopoly rights that incentivise development of future products and permitting higher drug prices to recoup the investment.

FDA 96
article thumbnail

Botanical drugs – what is the best way forward for regulatory and market approval?

European Pharmaceutical Review

4,6 Traditional Herbal Registration The Traditional Herbal Medicines Directive (Directive 2004/24/EC) is implemented in the UK by the Medicines (Traditional Herbal Medicinal Products for Human Use) Regulations 2005 and came into force on 30 April 2011. 2005 [cited 2024May]. 2012/1916). Available from: [link] Barber S.

FDA 103